Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 29, 2013. The report details a specific share repurchase transaction executed under authority granted by shareholders at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 927,000 Ordinary Shares of 25 pence each.
- Purchase Date: November 29, 2013.
- Price Range: Highest price paid was 1,621.50 pence per share; lowest price paid was 1,613.00 pence per share.
- Treasury Holdings (Settled): 509,932,909 shares (9.49% of total issued share capital).
- Treasury Holdings (Including Unsettled): 512,282,909 shares (10.54% of total voting rights).
- Shares in Issue (Excluding Treasury): 4,861,757,347 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 927,000 shares for Treasury. Consequently, the percentage of total voting rights held in Treasury increased to 10.54% when including unsettled purchases.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It is a compliance notification regarding the Financial Conduct Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (509,932,909 settled) against the company's latest annual report.
- Confirm the total issued share capital to validate the 9.49% Treasury ownership calculation.
- Check the status of the 2,350,000 shares (difference between settled and unsettled totals) to confirm settlement dates.
- Review the remaining authorization limit for share buybacks under the May 1, 2013 shareholder resolution.